The primary objective of the study is to compare the overall response rate (inclusive of complete response, partial response and hematologic improvement) per IWG 2006 criteria in patients with higher risk MDS treated with azacitidine with or without deferasirox achieved over the course of one year. Hematologic improvement must be maintained for at least 8 weeks.
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.
Latest Projects
The University of Texas at San Antonio
The University of Texas at San Antonio
Southwest Research Institute
Southwest Research Institute
The University of Texas at San Antonio
The University of Texas at San Antonio
